Abstract
Nodal peripheral T cell lymphomas (TCL) are rare entities with poor prognosis including ALK+ and ALK- systemic anaplastic T-cell lymphoma (ALCL), angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma – not otherwise specified. The role of PET in TCL is less well established compared to other lymphoma entities. Data are limited and based on single institution retrospective studies. At diagnosis, TCL are generally 18FDG-avid, with ALCL showing the highest avidity. Baseline PET reveals more disease sites, especially in extranodal areas, but with limited impact on clinical staging. Post-treatment PET seems to have a strong prognostic significance for outcome with a high positive, but a low negative predictive value for relapse. Interim PET, after 2–4 cycles of chemotherapy, is also strongly associated with outcome. In the majority of studies, a negative interim PET/CT scan is associated with a significantly superior PFS. The relatively high positive predictive value of interim-PET may prove extremely useful in identifying patients for early intensification of treatment. However the criteria for PET positivity need to be standardized and its prognostic value in TCL should be verified in future studies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Vose J, Armitage J, Weisenburger D (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124–4130
Elstrom R, Guan L, Baker G et al (2003) Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101:3875–3876
Tsukamoto N, Kojima M, Hasegawa M et al (2007) The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18FDGPET) and a comparison of 18FFDG- PET with 67gallium scintigraphy in the evaluation of lymphoma. Relation to histologic subtypes based on the World Health Organization classification. Cancer 110:652–659
Khong P-L, Pang CBY, Liang R et al (2008) Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol 87:613–621
Casulo C, Schöder H, Feeney J et al (2013) 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma. Leuk Lymphoma 54:2163–2167
Cahu X, Bodet-Milin C, Brissot E et al (2011) 18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group. Ann Oncol 22:705–711
Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, Ben-Barak A, Ben-Arie Y, Bar-Shalom R, Israel O (2010) (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 51:25–30
Li YJ, Li ZM, Xia XY et al (2013) Prognostic value of interim and posttherapy 18F-FDG PET/CT in patients with mature T-cell and natural killer cell lymphomas. J Nucl Med 54:507–515
Horwitz S, Coiffier B, Foss F et al (2015) Utility of 18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. Ann Oncol 26:774–779
Feeney J, Horwitz S, Gonen M, Schoder H (2010) Characterization of T-cell lymphomas by FDG PET/CT. AJR 195:333–340
Kako S, Izutsu K, Ota Y et al (2007) FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol 18:1685–1690
Juweid ME, Stroobants S, Hoekstra OS et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571–578
Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586
Meignan M, Barrington S, Itti E, Gallamini A, Haioun C, Polliack A (2014) Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 3–5 October 2012. Leuk Lymphoma 55:31–37
Haioun C, Itti E, Rahmouni A et al (2005) [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106:1376–1381
Tomita N, Hattori Y, Fujisawa S et al (2015) Post-therapy 18F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma. Ann Hematol 94(3):431–436
Sohn BS, Yoon DH, Kim KP et al (2013) The role of 18F-fluorodeoxyglucose positron emission tomography at response assessment after autologous stem cell transplantation in T-cell non-Hodgkin’s lymphoma patients. Ann Hematol 92:1369–1377
Pellegrini C, Argnani L, Broccoli A et al (2014) Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. Oncologist 19:746–750
Jung S-H, Ahn J-S, Kim Y-K et al (2015) Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma. BMC Cancer 15:198–206
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Angelopoulou, M.K., Vlachou, F.J., Kechagias, D.T. (2016). Peripheral T-Cell Lymphomas. In: Andreou, J., Kosmidis, P., Gouliamos, A. (eds) PET/CT in Lymphomas. Springer, Cham. https://doi.org/10.1007/978-3-319-27380-8_10
Download citation
DOI: https://doi.org/10.1007/978-3-319-27380-8_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-27378-5
Online ISBN: 978-3-319-27380-8
eBook Packages: MedicineMedicine (R0)